Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

234 Press Releases
DateTitleCompany
26 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire ,
Published by
PharmiWeb.com
25 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire plc,
Published by
PR Newswire
22 May 17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis Shire ,
Published by
PharmiWeb.com
22 May 17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire,
Published by
PharmiWeb.com
21 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire ,
Published by
PharmiWeb.com
19 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire plc,
Published by
PR Newswire
18 May 17 Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire ,
Published by
PharmiWeb.com
18 May 17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis Shire plc,
Published by
PR Newswire
18 May 17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire plc,
Published by
PR Newswire
16 May 17 Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association Shire plc,
Published by
PR Newswire
04 May 17 Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications Shire ,
Published by
PharmiWeb.com
01 May 17 Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
25 Apr 17 Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference Shire ,
Published by
PharmiWeb.com
25 Apr 17 Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference Shire plc,
Published by
PR Newswire
02 Dec 16 Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures Shire plc,
Published by
PR Newswire
27 Feb 17 CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism Shire ,
Published by
PharmiWeb.com
24 Apr 17 Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) Shire plc,
Published by
PR Newswire
01 Mar 17 Shire to Participate at the Cowen 37th Annual Healthcare Conference Shire plc,
Published by
PR Newswire
30 Mar 17 INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan Shire ,
Published by
PharmiWeb.com
19 Jan 17 U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD Shire plc,
Published by
PR Newswire
07 Mar 17 CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy Shire ,
Published by
PharmiWeb.com
23 Feb 17 New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease Shire,
Published by
PharmiWeb.com
23 Feb 17 Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases Shire ,
Published by
PharmiWeb.com
17 Apr 17 Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide Shire plc,
Published by
PR Newswire
23 Mar 17 SHIRE RECEIVES FDA FAST TRACK DESIGNATION FOR RECOMBINANT ADAMTS13 (SHP655) FOR TREATMENT OF HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA SHIRE ,
Published by
PharmiWeb.com
23 Mar 17 Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura Shire ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.